Skip to main content

RGLS

Stock
Health Care
Biotechnology

Performance overview

RGLS Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
85.47%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Company info

SectorHealth Care
IndustryBiotechnology
Employees38
Market cap$146.0M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+2.2
Credit+5.7
Liquidity-0.2
Inflation+1.2
Commodities-2.3
Interest Rates-0.7

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-6.50
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.

Benzinga (April 30, 2025)
Should You Buy Regulus (RGLS) After Golden Cross?

Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks Investment Research (April 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free